AbCellera Biologics (ABCL) vs Bausch Health Companies (BHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Bausch Health Companies (BHC) over the past year, gaining 176.1% versus a gain of 36.3%. Over five years, ABCL leads with a -30.7% price change compared with -67.4% for BHC. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $3.08 billion), about 1.0 times the size.
Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | BHC |
|---|---|---|
| Share price | $9.69 | $8.22 |
| Market cap | $3.16B | $3.08B |
| 1-day change | -7.45% | -3.97% |
| YTD return | +183.33% | +18.27% |
| 1-year return | +176.07% | +36.32% |
| 5-year return | -30.74% | -67.45% |
| Forward P/E | — | 1.89 |
| EPS (TTM) | $-0.48 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $10.27B |
| Revenue growth (YoY) | +160.56% | +6.66% |
| Net income (latest FY) | $-146.41M | $157.00M |
| Operating margin | -288.98% | 17.66% |
| Net margin | -194.88% | 1.53% |
| 52-week high | $15.02 | $9.04 |
| 52-week low | $2.75 | $4.33 |
| Distance from 52-week high | -35.46% | -9.07% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +92.67% | +2.19% |
| Average volume | 4.34M | 3.16M |
| Shares outstanding | 326.62M | 374.27M |
| Employees | 562 | 20,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed BHC by 139.7 percentage points over the past year.
- Bausch Health Companies is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +6.66%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
ABCL vs BHC FAQ
Which is bigger, AbCellera Biologics or Bausch Health Companies?
AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $3.08B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, ABCL or BHC?
ABCL returned +176.07% over the past 12 months, compared with +36.32% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Bausch Health Companies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.